<SEC-DOCUMENT>0001144204-17-033171.txt : 20170620
<SEC-HEADER>0001144204-17-033171.hdr.sgml : 20170620
<ACCEPTANCE-DATETIME>20170620101945
ACCESSION NUMBER:		0001144204-17-033171
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20170614
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170620
DATE AS OF CHANGE:		20170620

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOANALYTICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000720154
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				351345024
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23357
		FILM NUMBER:		17920018

	BUSINESS ADDRESS:	
		STREET 1:		2701 KENT AVE
		CITY:			WEST LAFAYETT
		STATE:			IN
		ZIP:			47906-1382
		BUSINESS PHONE:		3174634527

	MAIL ADDRESS:	
		STREET 1:		2701 KENT AVENUE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906-1382
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v469186_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
June 14, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">BIOANALYTICAL SYSTEMS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Exact name of registrant as specified in its charter)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Indiana</FONT></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">0-23357 </FONT></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">35-1345024</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction<BR>
 of incorporation or organization)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2701 KENT AVENUE</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WEST LAFAYETTE, INDIANA</P></TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">47906-1382</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Registrant's telephone number, including
area code: (765) 463-4527</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act(17CFR240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act(17CFR240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act(17CFR240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company&#9;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR CLEAR="ALL">
<B>Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 14, 2017, the
Board of Directors of Bioanalytical Systems, Inc. (the &ldquo;<U>Company</U>&rdquo;) unanimously elected Gregory C. Davis, Ph.D.
as an independent, Class III director. Dr. Davis&rsquo; term will expire at the 2018 annual meeting of shareholders. The Board
of Directors has not determined the committees of the Board of Directors to which Dr. Davis will be named. The Company will disclose
that information once determined.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a director of the
Company, Dr. Davis will receive compensation as a non-employee director in accordance with the Company&rsquo;s non-employee director
compensation practices described in the Company&rsquo;s Proxy Statement on Schedule 14A filed with the Securities and Exchange
Commission on January 30, 2017. This compensation generally consists of cash payments (annual cash retainers and board and committee
meeting fees) and such stock option awards as may be granted from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of the press
release announcing the election of Dr. Davis is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01 Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Exhibits:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">99.1</TD><TD>Press Release dated June 20, 2017</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Bioanalytical Systems, Inc. </FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 48%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 3%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 30%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 19%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Date: June 20, 2017</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/
    Jill C. Blumhoff</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Jill C. Blumhoff</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Chief Financial Officer,</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Vice President of Finance</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit Index</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><U>Exhibit No.</U></TD><TD STYLE="text-align: justify"><U>Description</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">99.1</TD><TD>Press Release dated June 20, 2017</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.8in; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v469186_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; font-size: 10pt; text-indent: 0">&nbsp;<IMG SRC="image_002.jpg" ALT=""></TD>
    <TD STYLE="width: 50%; padding: 0; font-size: 10pt; text-indent: 0; text-align: right"><IMG SRC="image_003.jpg" ALT="">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 81%; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR MORE INFORMATION:</B></FONT></TD>
    <TD STYLE="width: 19%; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company Contact:&nbsp;</B></FONT></TD></TR>
<TR>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jill Blumhoff&nbsp;</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer &amp; </FONT></TD></TR>
<TR>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President of Finance&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone:&nbsp;&nbsp;765.497.8381&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>jblumhoff@BASinc.com</U></FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0; text-align: right; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0.5in; text-align: center"><B>BASi Names Dr. Gregory
C. Davis to Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0"><B>WEST LAFAYETTE, IN</B>, June 20, 2017 -- <B>Bioanalytical
Systems, Inc. (NASDAQ:BASI) (&ldquo;BASi&rdquo; or the &ldquo;Company&rdquo;)</B> today announced that the board of directors unanimously
elected Dr. Gregory C. Davis as a director effective June 14, 2017. This action brings the number of directors to four.<BR>
<BR>
Larry Boulet, BASi&rsquo;s Chairman of the Board, commented, &quot;We are delighted that Dr. Davis has joined our board. His strong
background in the pharmaceutical industry and proven leadership qualities will prove particularly valuable as we continue to focus
on strategies that drive growth for BASi.&quot;<BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify">Dr. Davis is currently running
<FONT STYLE="background-color: white">his own consulting firm, which he founded in 2012, assisting companies with regulatory and
control strategy and product development issues. &nbsp;In 2014, Greg joined Calibrium, LLC as Vice President of CMC, Regulatory,
and Quality. Calibrium was developing novel biotheraputics for the treatment of diabetes. The company was sold to Novo Nordisk
in late 2015. From 1992 to 2012, Dr. Davis held various leadership positions at Eli Lilly&nbsp;in Biotechnology Product Development,
Global Regulatory Affairs, Global Brand Teams, and Quality. One of the highlights of his Lilly career was being COO of the Xigris
Product Team. Xigris was the first biotechnology product ever approved for the treatment of severe sepsis. When Greg retired from
Eli Lilly in December of 2012, he was Executive Director and Senior Principle Fellow in Global Regulatory Affairs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify">Dr. Davis <FONT STYLE="background-color: white">has
held numerous leadership positions within the Pharmaceutical Research and Manufacturers Association (PhRMA), the United States
Pharmacopeia (USP), and the Biotechnology Industry Organization (BIO). He also served for five years as the PhRMA liaison to the
International Conference on Harmonization (ICH) for Q5/Q6 Biotechnology topics. He coauthored several of the ICH guidances on registration
standards for biotechnology products which are still in use today<FONT STYLE="color: #333333">. </FONT>Dr. Davis </FONT>received
his bachelor&rsquo;s degree from Southeast Missouri State University and his Ph.D. in Analytical Chemistry from Purdue University
studying under Dr. Peter Kissinger, founder of BASi.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify"><B>About Bioanalytical Systems,
Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify">BASi is a pharmaceutical development
company providing contract research services and monitoring instruments to the world's leading drug development companies and
medical research organizations. The Company focuses on developing innovative services and products that increase efficiency and
reduce the cost of taking a new drug to market. Visit <U>www.BASinc.com</U> for more information about BASi.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify"><I>This release may contain forward-looking
statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes
in the market and demand for our products and services, the development, marketing and sales of products and services, changes
in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings
with the Securities and Exchange Commission.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; padding: 0; font-size: 10pt; text-indent: 0; text-align: right">&nbsp;<IMG SRC="image_004.jpg" ALT=""></TD>
    <TD STYLE="width: 10%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 45%; padding: 0; font-size: 10pt; text-indent: 0; text-align: left"><IMG SRC="image_005.jpg" ALT="">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !1 .8# 2(  A$! Q$!_\0
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M4=>#^8K!8F"QDOK&J6B[+Y&[PM1X*"PVC>K[OYG<ZKX&T34HW\NV6TG(^62
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? "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X 3 # 2(  A$! Q$!_\0
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  M >X# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ1Y*HT*D G&3R.IP.?:I(],T^*-(X[&V1$D$JJL*@*X_B QP?>K=% !1110
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0BM$D#J3>K;^\****H@__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Y 6D# 2(  A$! Q$!_\0
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M?_GMI'_?F7_XJC9XG_Y[:1_WYE_^*H VJ*Q=GB?_ )[:1_WYE_\ BJ-GB?\
MY[:1_P!^9?\ XJ@#:HK%V>)_^>VD?]^9?_BJ-GB?_GMI'_?F7_XJ@#:HK%V>
M)_\ GMI'_?F7_P"*HV>)_P#GMI'_ 'YE_P#BJ -JBL79XG_Y[:1_WYE_^*HV
M>)_^>VD?]^9?_BJ -JBL79XG_P">VD?]^9?_ (JC9XG_ .>VD?\ ?F7_ .*H
M VJ*Q=GB?_GMI'_?F7_XJC9XG_Y[:1_WYE_^*H VJ*Q=GB?_ )[:1_WYE_\
MBJ-GB?\ Y[:1_P!^9?\ XJ@#:HK%V>)_^>VD?]^9?_BJ-GB?_GMI'_?F7_XJ
M@#:HK%V>)_\ GMI'_?F7_P"*HV>)_P#GMI'_ 'YE_P#BJ -JBL79XG_Y[:1_
MWYE_^*HV>)_^>VD?]^9?_BJ -JBL79XG_P">VD?]^9?_ (JC9XG_ .>VD?\
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MC_A(=:_Z"]__ .!+_P"-9M%'M:G\S^]_YA[&G_*ON7^1I?\ "0ZU_P!!>_\
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MI-:-WWZG34553FX)ZI6VZ&U::+9Z)J&L*^^0Q:;Y\)DC1FCSU]MP]1[UF_\
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M<<# JJU>C*$DGJ_^#;IT)H8>O&<&UHO/TOUZG/4445Y)ZX44Z-'ED6-%+.Q
M50,DFNP_X5SK7K;?]_/_ *U=N%P,\2FXZ6.'%X^GAFE)7;/6*P-5_P"1O\/?
M2Y_] %;]8&J_\C?X>^ES_P"@"OKCXX\X\>?\CE??2/\ ]%K7-UTGCS_D<K[Z
M1_\ HM:YNOC,5_'GZO\ ,^WPG^[P]%^04445SG0%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%:&A_\ (?T__KYC_P#0A6U"G[6I&%]S'$5?94I5+7LC
MM_ OA&2*5-7U&+:PYMX7'.?[Y'\OS]*]#HHK["C1A1@H0V1\77K3K3=2>[/_
!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
